6 research outputs found
Additional file 12: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
Details on participating institutional or clinical sites at which Institutional Review Boards or Ethics Committees approved the clinical trials included in the study. (DOCX 59 kb
Additional file 1: of A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis
A comprehensive summary of sample sizes and cohorts in pharmacogenetics studies in the field of multiple sclerosis. (DOCX 23 kb
Additional file 5: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Table S5. Pathway analysis of alternatively spliced genes identified after high dose treatment with pridopidine. (XLSX 31 kb
Additional file 4: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Table S4. qPCR validation of striatal gene expression identified in RNAseq and pathway analysis. (XLSX 10 kb
Additional file 1: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Table S1. Adjusted p-val range and fold change range for differential expression and DUEJ genes meeting adj p-val < 0.05 cutoff. (XLSX 11 kb
Additional file 3: of Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse
Table S3. Transcription factor enrichment analysis of genes differentially expressed in the mouse striatum. (XLSX 18 kb